The International Trade Commission is publishing notices in the July 3 Federal Register on the following AD/CV injury, Section 337 patent, and other trade proceedings (any notices that warrant a more detailed summary will appear in another ITT article):
The International Trade Commission will review part of an administrative law judge’s initial determination in the ITC’s section 337 patent investigation of certain ink application devices and components thereof and methods of using the same (337-TA-832). The ALJ’s initial determination had found all three respondents, T-Tech Tattoo Devices Inc., Tiwu Beyond Tattoo Equipments Co., Ltd., and Guangzhou Pengcheng Cosmetology Firm, in default after they failed to respond to the ALJ’s order to show cause. However, the ITC found that T-Tech never received the order because of problems with delivery, and determined to review the ALJ’s finding that T-Tech was in default.
The International Trade Commission voted to institute an investigation of certain integrated circuit packages provided with multiple heat-conducting paths and products containing same (337-TA-851). The products at issue in this investigation are IC chips incorporated into, for example, televisions.
The International Trade Administration published notices in the July 3 Federal Register on the following AD/CV proceedings (any notices that announce changes to AD/CV duty rates, the scope, affected firms, or effective dates will be detailed in another ITT article):
The International Trade Administration issued the final results of the administrative review of the antidumping duty order on folding metal tables and chairs from China (A-570-868), which sets an AD cash deposit rate of zero for one exporter. This rate, which is effective July 5, is expected to be implemented by U.S. Customs and Border Protection soon.
On July 2 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
During the week of June 25 - July 1, the Food and Drug Administration modified the following existing Import Alerts (not otherwise listed on the FDA's new and revised import alerts page) on the detention without physical examination of:
A draft guidance is now available on labeling requirements for certain over-the-counter internal analgesic, antipyretic, and antirheumatic drug products that contain acetaminophen, said the Food and Drug Administration (FDA). The draft guidance, entitled “Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use -- Labeling for Products That Contain Acetaminophen,” is intended to inform manufacturers of the circumstances in which the FDA intends to enforce the liver warning requirement for such products. To ensure consideration of comments before the final version of this guidance is released, comments should be submitted by Sept. 4, the FDA said. The draft guidance is available here.
The Food and Drug Administration will not allow foreign manufacturers outside of Mexico and Canada to participate in its Secure Supply Chain pilot program, ITT has learned. Although the FDA’s July 20 Federal Register notice did not explicitly say that only U.S., Canadian and Mexican manufacturers could take part, Sara Clark-Lynn of the FDA Office of Public Affairs confirmed that only C-TPAT Tier II and III members are eligible for the pilot program, and acknowledged that “only foreign manufacturers located in Canada and Mexico are eligible to become C-TPAT members.”
On July 2 the Foreign Agricultural Service issued the following GAIN reports: